Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration

Full text
Author(s):
Macedo de Moraes, Ruan Carlos [1] ; Singulani, Monique Patricio [1] ; de Goncalves, Alisson Carvalho [2] ; Portari, Guilherme Vannucchi [2] ; Torrao, Andrea da Silva [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo - Brazil
[2] Univ Fed Triangulo Mineiro, Inst Hlth Sci, Dept Nutr, Uberaba, MG - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Experimental Gerontology; v. 141, NOV 2020.
Web of Science Citations: 1
Abstract

It is well known that patients with Alzheimer's disease (AD) have imbalances in blood thiamine concentrations and lower activity of thiamine-dependent enzymes. Benfotiamine, a more bioavailable thiamine analog, has been proposed as an alternative to counteract these changes related to thiamine metabolism. Thus, our study aimed to analyze the effects of benfotiamine supplementation on brain thiamine absorption, as well as on parameters related to neuronal energy metabolism and disease progression in an experimental model of sporadic AD induced by intracerebroventricular injection of streptozotocin (STZ) in rats. The supplementation with 150 mg/kg of benfotiamine for 30 days increased the concentrations of thiamine diphosphate in the hippocampus and entorhinal cortex. This led to an improvement in mitochondria enzymes and insulin signaling pathway, with inactivation of GSK3 alpha/beta and ERK1/2, which are two tau-kinases related to the progression of AD, which could decrease tau hyperphosphorylation and apoptosis signaling. Besides, we observed an increased amount of Glun2b subunit of NMDA receptors, decreased inflammation, and improvement of cognitive deficit. Together, these results suggest that benfotiamine could be a potential therapeutic approach in the treatment of sporadic AD. (AU)

FAPESP's process: 17/10801-1 - Benfotiamine and thyroid hormone: influence on neuronal energy metabolism and neurodegeneration progression in an experimental model similar to Alzheimer's Disease
Grantee:Andréa da Silva Torrão
Support Opportunities: Regular Research Grants